Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.62 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | CPA1 | P15085 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPA3 | P15088 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methamphetamine SCHEMBL6462454 | 1.00 | TAAR1 (0.62) | TAAR1SLC18A2SIGMAR1ALPIPKM | |
| Methamphetamine SCHEMBL6456321 | 0.96 | TAAR1 (0.57) | TAAR1SLC18A2SIGMAR1ALPIPKM | |
| Methamphetamine SCHEMBL6456330 | 0.96 | TAAR1 (0.57) | TAAR1SLC18A2SIGMAR1ALPIPKM | |
| Aspartic Acid SCHEMBL29223446 | 0.85 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Levamfetamine SCHEMBL4596702 | 0.84 | SLC6A2 (0.63) | TAAR1SIGMAR1ALPIPKMPTGS1 | |
| Dextroamphetamine SCHEMBL3681578 | 0.84 | SLC6A2 (0.63) | TAAR1SIGMAR1ALPIPKMPTGS1 | |
| Amphetamine SCHEMBL1030967 | 0.84 | SLC6A2 (0.63) | TAAR1SIGMAR1ALPIPKMPTGS1 | |
| Amphetamine SCHEMBL1030966 | 0.84 | SLC6A2 (0.63) | TAAR1SIGMAR1ALPIPKMPTGS1 | |
| Phenylalanine SCHEMBL17766088 | 0.83 | SLC7A5 (0.71) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dextroamphetamine SCHEMBL21158800 | 0.83 | SLC6A2 (0.61) | TAAR1SIGMAR1ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2004103283-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CENTRAL NERVOUS SYSTEM STIMULANT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040176378-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | GAP43, PTGS2, CNR2 | TAAR1 54/4885SLC18A2 252/4885SIGMAR1 951/4885 |
| US-20040176378-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system | HTR2C, HTR2A, PTGS2 | TAAR1 72/4885SLC18A2 321/4885SIGMAR1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.